Search

Your search keyword '"Tien, Feng-Ming"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Tien, Feng-Ming" Remove constraint Author: "Tien, Feng-Ming"
136 results on '"Tien, Feng-Ming"'

Search Results

2. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

3. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations

4. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification

8. Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

9. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission

12. Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/Neoplasms

14. Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification

15. P721: VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION

18. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia

20. Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification

22. Additional file 1 of Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis

25. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.

26. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia

27. Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

28. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission

33. Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

35. The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

36. Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy

37. Automatic Bone Marrow Cell Identification and Classification By Deep Neural Network

39. Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3-ITD Patients

40. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor inde novoacute myeloid leukemia patients

41. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA

43. The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)

44. Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008–2013

45. The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation

47. Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novoaml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3-ITD Patients

Catalog

Books, media, physical & digital resources